# Vir Biotechnology Inc. (VIR)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $1.14B  
**Price:** $8.25 (-3.06%)

> Vir Biotechnology Inc. is a clinical-stage biopharmaceutical company that discovers, develops, and advances immune-based therapies to treat and prevent serious infectious diseases and cancer. The company leverages its next-generation antibody platform and PRO-XTEN protease-releasable masking technology to power the immune system against unmet medical needs. Its lead program features the combination of tobevibart, a broadly neutralizing monoclonal antibody, and elebsiran, a siRNA targeting hepatitis B virus, in Phase 3 trials through the ECLIPSE registrational program for chronic hepatitis delta virus. In oncology, Vir Biotechnology advances PRO-XTEN dual-masked T-cell engagers, including VIR-5500 targeting PSMA for metastatic castration-resistant prostate cancer, VIR-5818 for HER2-expressing tumors, and VIR-5525 for EGFR-expressing solid tumors, all in Phase 1 development. Preclinical efforts target influenza, RSV, human metapneumovirus, HPV, HIV, and other indications. Founded in 2016 and headquartered in San Francisco, California, Vir Biotechnology focuses on immunology-driven innovation across infectious diseases and oncology to deliver potentially transformative medicines.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $69M | — | -$479M | -$438M | — |
| 2024 | $74M | — | -$587M | -$522M | — |
| 2023 | $86M | — | -$684M | -$615M | — |
| 2022 | $1.62B | — | $833M | $516M | — |
| 2021 | $1.10B | — | $421M | $529M | — |
| 2020 | $76M | — | -$297M | -$299M | — |
| 2019 | $8M | — | -$178M | -$175M | — |
| 2018 | $11M | — | -$119M | -$116M | — |
| 2017 | $3M | — | -$81M | -$70M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $1.00B | $238M | $765M | $232M | — |
| 2024 | $1.40B | $248M | $1.15B | $223M | — |
| 2023 | $1.92B | $329M | $1.59B | $242M | — |
| 2022 | $2.80B | $724M | $2.08B | $849M | — |
| 2021 | $1.95B | $522M | $1.43B | $348M | — |
| 2020 | $919M | $202M | $717M | $437M | — |
| 2019 | $512M | $88M | $424M | $109M | — |
| 2018 | $192M | $62M | -$179M | $48M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$392M | $5M | -$397M |
| 2024 | -$446M | $7M | -$454M |
| 2023 | -$779M | $22M | -$800M |
| 2022 | $1.66B | $68M | $1.60B |
| 2021 | -$48M | $22M | -$69M |
| 2020 | -$191M | $7M | -$197M |
| 2019 | -$130M | $9M | -$139M |
| 2018 | -$94M | $8M | -$102M |
| 2017 | -$66M | $3M | -$69M |

Source: [CompaniesByCap](https://companiesbycap.com/company/VIR)